CD8 positive	Non Small Cell Lung Cancer	CD8 positive	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
CD8 positive	Triple Negative Breast Cancer	CD8 positive	Triple Negative Breast Cancer	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3
CD8 positive	Non Small Cell Lung Cancer	CD8 positive	Non Small Cell Lung Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
CD8 positive	Melanoma	CD8 positive	Melanoma	nivolumab + CMP-001 Sensitive: C3 – Early Trials nivolumab + CMP-001 Sensitive : C3	nivolumab + CMP-001 Sensitive: C3 – Early Trials nivolumab + CMP-001 Sensitive : C3
CD8 positive	Glioblastoma	CD8 positive	Glioblastoma	efineptakin alfa Sensitive: D – Preclinical efineptakin alfa Sensitive : D	efineptakin alfa Sensitive: D – Preclinical efineptakin alfa Sensitive : D
CD8 positive	Fibrosarcoma	CD8 positive	Fibrosarcoma	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D
CD8 positive	Colorectal Cancer	CD8 positive	Colorectal Cancer	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D

CD8 positive

Associations